Protective role of butyrate in obesity and diabetes: New insights
using in vivo fiber photometry demonstrated that both GIP and GLP-1 analogs at pharmacologic doses inhibited AgRP neurons in proportion to their anorexigenic action
In the SURMOUNT trials, nausea affected 12 to 18 percent of participants at lower doses and higher percentages at escalating doses
The risk of bias in the included cohort studies was assessed using Newcastle-Ottawa Quality Assessment Form for Cohort Studies (NOS)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: from discovery to clinical proof of concept
GlycoLemon , a new and exciting ingredient featuring Eriomin , which has been shown in clinical studies to significantly reduce hyperglycemia, enhance GLP-1 levels, decrease systemic inflammation, and improve gut health